BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

FDA approved Ukoniq umbralisib from TG Therapeutics Inc. (NASDAQ:TGTX) to treat relapsed or refractory marginal zone lymphoma following anti-CD20 treatment, or relapsed or refractory follicular lymphoma in a fourth-line setting. TG believes the once-daily oral...
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185) and then challenged with mouse-adapted SARS-CoV-2 had no detectable virus in the lungs and nose...
BioCentury | Jan 13, 2020
Company News

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease. Monday’s deal is Biogen’s second in...
BioCentury | Feb 5, 2019
Distillery Therapeutics


INDICATION: Renal cancer In vitro and cell culture studies identified an aminothiazole-based negative allosteric modulator (NAM) of CSNK2 that could help treat renal cell carcinoma (RCC). Chemical synthesis and in vitro testing of aminothiazole analogs...
BioCentury | Apr 13, 2018
Clinical News

ProMIS identifies new beta amyloid epitope to treat AD

Researchers at the University of British Columbia reported preclinical data showing that PMN300 decreased soluble beta amyloid aggregates and neurotoxicity in the brain in two mouse models of Alzheimer's disease. In a paper published in...
BioCentury | Jan 12, 2018
Company News

Exelixis, StemSynergy in CSNK1A activator deal

...and StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha... treat cancer. The partners will conduct preclinical and clinical studies of compounds from StemSynergy's CSNK1A...
...Miami, Fla. Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Business: Cancer Elizabeth S. Eaton Exelixis Inc. StemSynergy Therapeutics Inc. Casein kinase 1 alpha (CSNK1A) (CKI-alpha)...
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
BioCentury | Aug 16, 2017
Distillery Therapeutics


INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active...
BioCentury | Jul 18, 2017
Distillery Therapeutics


...Colorectal cancer Patient sample, in vitro , cell culture and mouse studies identified a benzamide-based CSNK1A...
...could help treat Wnt signaling-driven colorectal cancer. In colorectal cancer patients, low tumor levels of CSNK1A...
...a benzamide-based compound that bound CSNK1A with a K d of 32 nM, and inhibited CSNK1A...
BioCentury | Feb 28, 2017
Distillery Therapeutics


INDICATION: Huntington's disease (HD) Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal and gastrocnemius muscle tissue samples...
Items per page:
1 - 10 of 31